1-3 of 3
ocrelizumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Crystal Structure Analysis Reveals That the Novel Type II Anti-CD20 Antibody GA101 Interacts with a Similar Epitope as Rituximab and Ocrelizumab but in a Fundamentally Different Way.

Gerhard J Niederfellner, Alfred Lammens, Manfred Schwaiger, Guy Georges, Kornelius Wiechmann, Andreas Franke, Wolfgang Schaefer, Stefan Jenewein, Jerry Slootstra, Ekkehard Moessner, Pablo Umana, Karl-Peter Hopfner, Christian Klein
Journal: Blood
Blood (2009) 114 (22): 3726.
https://doi.org/10.1182/blood.V114.22.3726.3726
Published: 2009
Journal Articles

Protein Tomography Analysis Shows That CD20 Molecules Bound by Different Type I and Type II Anti-CD20 Antibodies Are Organized in Different Protein Complexes.

Gerhard J Niederfellner, Annika Braennstroem, Frida Lindstrom, Magnus Jansson, Marika Lundin, Wolfgang Schaefer, Olaf Mundigl, Pablo Umana, Christian Klein
Journal: Blood
Blood (2009) 114 (22): 4782.
https://doi.org/10.1182/blood.V114.22.4782.4782
Published: 2009
Journal Articles

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Paula Marlton, Umberto Vitolo, Ola Linden, John Seymour, Michael Crump, Bertrand Coiffier, Alessandro Pulsoni, Andrew Belch, Erika Lerch, Eva Kimby, Kristina Arnljots, Elisabeth Wassner, Myriam Mendila
Journal: Blood
Blood (2007) 110 (11): 645.
https://doi.org/10.1182/blood.V110.11.645.645
Published: 2007